미국 · 보도자료 · KAPA · 2026-10-06 11:30
전이성 전립선암 치료제 ENV-105, 임상 2상 중간 결과서 유의미한 효능 확인
LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The interi
